Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Polyphor AG
  6. News
  7. Press Releases
    POLN   CH0106213793

POLYPHOR AG

(POLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société POLYPHOR AG
06/28POLYPHOR : provides update on the Phase III FORTRESS study of balixafortide in patients wi..
EQ
06/28Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients W..
GL
06/08POLYPHOR HOSTING KEY OPINION LEADER : The Need for Novel Therapies for Severe Infections ..
EQ
06/08POLYPHOR HOSTING KEY OPINION LEADER : The Need for Novel Therapies for Severe Infections ..
GL
06/01POLYPHOR : balixafortide demonstrates consistent dual action anti-viral and anti-inflammat..
EQ
06/01Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflam..
GL
05/18POLYPHOR : to present at the UBS Global Healthcare Virtual Conference
EQ
05/18Polyphor to Present at the UBS Global Healthcare Virtual Conference
GL
04/06POLYPHOR : Annual General Meeting 2021
PU
03/15POLYPHOR : publishes invitation to Annual General Meeting 2021
PU
03/15POLYPHOR : publishes invitation to Annual General Meeting 2021
EQ
03/05POLYPHOR : announces financial results for the full-year 2020
EQ
03/05Polyphor Announces Financial Results for the Full-Year 2020
GL
03/01POLYPHOR : to present full-year 2020 financial results on March 5
AQ
02/26POLYPHOR : to present full-year 2020 financial results on March 5
EQ
02/26Polyphor to Present Full-Year 2020 Financial Results on March 5
GL
01/05Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Part..
GL
2020Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic..
GL
2020POLYPHOR : announces third positive Data Safety Monitoring Board recommendation to continu..
AQ
2020POLYPHOR : receives an additional USD 2.3 million award from CARB-X to support ongoing dev..
AQ
2020Polyphor Announces Third Positive Data Safety Monitoring Board (DSMB) Recommendation to..
GL
2020Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing De..
GL
2020POLYPHOR : receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to supp..
AQ
2020POLYPHOR : Cystic Fibrosis Foundation Awards Up to $3.3M to Polyphor for Inhaled Version o..
AQ
2020POLYPHOR : receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to supp..
EQ
2020POLYPHOR : receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to sup..
AQ
2020Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to su..
GL
2020POLYPHOR : to Host an Expert Perspectives Webinar on Innovative IO Approaches for the Trea..
AQ
2020POLYPHOR : to Host an Expert Perspectives Webinar on Innovative IO Approaches for the Trea..
EQ
2020POLYPHOR : completes recruitment in Phase III trial of balixafortide in metastatic breast ..
AQ
2020POLYPHOR : completes recruitment in Phase III trial of balixafortide in metastatic breast ..
AQ
2020POLYPHOR : completes recruitment in Phase III trial of balixafortide in metastatic breast ..
EQ
2020Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast..
GL
2020POLYPHOR : receives CARB-X award of up to USD 18.44 million to support development of new ..
AQ
2020POLYPHOR : receives CARB-X award of up to USD 18.44 million to support development of new ..
AQ
2020POLYPHOR : receives CARB-X award of up to USD 18.44 million to support development of new ..
EQ
2020Polyphor receives CARB-X award of up to USD 18.44 million to support development of new..
GL
2020POLYPHOR : announces closing of Fosun Pharma licensing agreement for balixafortide in Chin..
AQ
2020POLYPHOR : Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in Chin..
AQ
2020POLYPHOR : announces closing of Fosun Pharma licensing agreement for balixafortide in Chin..
EQ
2020Polyphor Announces Closing of Fosun Pharma Licensing Agreement for balixafortide in Chi..
GL
2020POLYPHOR : to present at the H.C. Wainwright Global Investment Conference
AQ
2020POLYPHOR : to present at the H.C. Wainwright Global Investment Conference
EQ
2020POLYPHOR : announces financial results for the first half 2020
AQ
2020POLYPHOR : announces financial results for the first half 2020
EQ
2020POLYPHOR : and Fosun Pharma announce exclusive licensing agreement for balixafortide in Ch..
AQ
2020POLYPHOR : and Fosun Pharma announce exclusive licensing agreement for balixafortide in Ch..
EQ
2020POLYPHOR : announces second positive Data Safety Monitoring Board recommendation to contin..
AQ
2020POLYPHOR : announces second positive Data Safety Monitoring Board recommendation to contin..
EQ
2020POLYPHOR : strengthens financial flexibility with CHF 19.3 million equity-linked financing
AQ
2020POLYPHOR : strengthens financial flexibility with CHF 19.3 million equity-linked financing
EQ
2020POLYPHOR : shareholders approve all proposals at the Annual General Meeting 2020
AQ
2020POLYPHOR : shareholders approve all proposals at the Annual General Meeting 2020
EQ
2020POLYPHOR : announces acceptance of balixafortide abstract at the American Society of Clini..
AQ
2020POLYPHOR : announces acceptance of balixafortide abstract at the American Society of Clini..
EQ
2020POLYPHOR : publishes invitation to the Annual General Meeting 2020
AQ
2020POLYPHOR : publishes invitation to the Annual General Meeting 2020
EQ
2020POLYPHOR : announces financial results for the full-year 2019
AQ
2020POLYPHOR : announces financial results for the full-year 2019
EQ
2020POLYPHOR : announces positive Data Safety Monitoring Board recommendation to continue Phas..
AQ
2020POLYPHOR : announces positive Data Safety Monitoring Board (DSMB) recommendation to contin..
EQ
2020POLYPHOR : announces progress of the Phase III immuno-oncology program with balixafortide...
EQ
2020POLYPHOR : appoints Gokhan Batur as Chief Executive Officer
AQ
2020POLYPHOR : appoints Gökhan Batur as Chief Executive Officer
EQ
2019POLYPHOR : announces changes to its Board of Directors
EQ
2019POLYPHOR : announces changes to its Board of Directors
PU
2019POLYPHOR : and the University of Zurich announces publication in 'Nature' of the unique me..
EQ
2019POLYPHOR : to present at the H.C. Wainwright Global Investment Conference
EQ
2019POLYPHOR : announces financial results for the first half 2019 and realigns strategy
EQ
2019POLYPHOR : to host a Key Opinion Leader Meeting in New York on novel approach-es to the tr..
EQ
2019POLYPHOR : closes the Phase III PRISM studies of murepavadin intravenous formulation and e..
EQ
2019POLYPHOR : appoints Frank Weber as new Chief Medical and Development Officer
EQ
2019POLYPHOR : to present its antibiotic programs at the American Society of Microbiology (ASM..
EQ
2019POLYPHOR : announces enrollment of first patient in FORTRESS Phase III clinical trial for ..
EQ
2019POLYPHOR : presents new in-vivo efficacy and tolerability data for a potential inhaled adm..
EQ
1  2Next
Upcoming event on POLYPHOR AG